SEATTLE, May 30, 2012 /PRNewswire/ -- Aequus BioPharma, Inc. ("Aequus"), a majority owned subsidiary of Cell Therapeutics, Inc.

THOUSAND OAKS, Calif., May 23, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced voting results from the Company's Annual Meeting of Stockholders, held at the Four Seasons Hotel, Westlake

In the news release, Amgen's BiTE® Antibody Blinatumomab (AMG 103) Achieved High Rate of Complete Response in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, issued 16-May-2012

THOUSAND OAKS, Calif., May 16, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced updated results from a Phase 2 study that showed treatment with blinatumomab (AMG 103) helped achieve

THOUSAND OAKS, Calif., May 16, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN) announced today results from an exploratory biomarker analysis evaluating MET expression as a predictor of clinical